Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Japanese pharmaceutical firm Eisai and UK-based genome analytics firm Genomics have entered into collaboration agreement to use the latter’s statistical in analyses of large-scale genotype/phenotype data to inform Eisai’s drug development.
Subscribe to our email newsletter
Under the deal, the data will also be used to inform target selection, target validation, indication selection and repositioning.
The deal will see Genomics partner with Eisai’s new Integrated Human Genomics (IHGx) Research Unit, which operates directly under the supervision of Eisai Product Creation Systems’ chief clinical officer.
Eisai global head of Genetics & Human Biology and director of the IHGx Research Unit Dr Nadeem Sarwar said: "Genomics’ founders are internationally recognized leaders in the analysis and interpretation of human genetic data.
"This collaboration is another indication of Eisai’s commitment to leveraging genomic knowledge to accelerate the discovery and development of impactful new medicines."
Eisai’s IHGx Research Unit combines dedicated quantitative, wet-lab biology and chemistry expertise and resource within an autonomous and highly collaborative R&D innovation unit.
IHGx focuses on neurodegeneration, auto-immune diseases and oncology, employing entrepreneurial and collaborative business models, to catalyse delivery of new and targeted therapeutics from human genetics to patients.